Gilead Sciences Inc. has disclosed protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Glenmark Pharmaceuticals Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated kinase 3 (IRAK-3; IRAK-M) targeting moiety via linker reported to be useful for the treatment of cancer.
Bial-Portela & Ca SA has identified orexin OX1 receptor antagonists reported to be useful for the treatment of cognitive, sleep, anxiety and eating disorders, depression, obesity, schizophrenia, substance abuse and dependence, among others.
2A Biosciences Inc. has synthesized tryptamine derivatives acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric, neurodegenerative, neurodevelopmental, inflammatory and eye disorders.
Fudan University has disclosed phosphatidylcholine:ceramide cholinephosphotransferase 2 (SGMS2; SMS2) inhibitors reported to be useful for the treatment of cancer, atherosclerosis, dry eye, pulmonary edema, fatty liver, obesity, type 2 diabetes and Alzheimer’s disease.
The U.S. Court of Appeals for the Federal Circuit occasionally remands a patent litigation case to district court for a variety of reasons, as seen in a decision involving Trudell Medical and D R Burton.
Bsense Bio Therapeutics Ltd. has disclosed new potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators and transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonists reported to be useful for the treatment of neuropathic pain, pruritus and tinnitus.
Neumora Therapeutics Inc. has patented NMDA receptor positive allosteric modulators reported to be useful for the treatment of autoimmune disease, infections, neurological and psychiatric disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new benzimidazoles acting as serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of rheumatoid arthritis, metabolic dysfunction-associated steatohepatitis (MASH), giant cell arteritis, primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.